Secondary prevention of coronary heart disease in elderly population of Turkey: A subgroup analysis of ELDERTURK study.
Aged
Aged, 80 and over
Angiotensin-Converting Enzyme Inhibitors
/ therapeutic use
Coronary Disease
/ epidemiology
Female
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Incidence
Life Style
Male
Platelet Aggregation Inhibitors
/ therapeutic use
Prevalence
Prognosis
Retrospective Studies
Risk Factors
Secondary Prevention
/ methods
Survival Rate
/ trends
Turkey
/ epidemiology
aging
coronary disease
drugs
epidemiology
prevention
treatment
Journal
Cardiology journal
ISSN: 1898-018X
Titre abrégé: Cardiol J
Pays: Poland
ID NLM: 101392712
Informations de publication
Date de publication:
2019
2019
Historique:
received:
04
09
2017
accepted:
10
09
2017
pubmed:
6
10
2017
medline:
4
12
2019
entrez:
6
10
2017
Statut:
ppublish
Résumé
Secondary prevention plays an important role after acute coronary event due to high risk of adverse events in elderly. In present study we aimed to evaluate the lifestyle, management of risk factors and medical treatment for secondary protection in elderly patients with known coronary heart disease (CHD). ELDERTURK is a non-interventional, multi-centered, observational study, which included total of 5694 elderly patients ( > 65 years) from 50 centers in Turkey. In this study elderly patients from the ELDERTURK population with known CHD were evaluated for cardiovascular risk factors, comor- bidities and medication usage. A total of 2976 (52.3% of study) out of 5694 patients included in the ELDERTURK study were evaluated. All had known CHD with a mean age of 73.4 ± 6.2 years and 60.3% were male. 13.0% of patients were smokers, 42.4% were overweight and 21.1% were obese. Only 23.6% of patients reported to do regular exercise, 73.4% had history of hypertension, 47.4% had dyslipidemia and 33.9% had diabetes mellitus. The rate of patients with systolic blood pressure > 140 mmHg were 31.1% and only 13.9% of patients had a recommended ≤ 70 mg/dL level of low-density lipoprotein cholesterol. Anti- platelet, statin, beta-blocker and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker usage was limited to 27.3%. The ELDERTURK study shows that many patients with CHD have a high prevalence of modifiable risk factors and unhealthy lifestyle. Apart from this, many patients are not receiving thera- peutic intervention and as a consequence most were not achieving the recommended goals.
Sections du résumé
BACKGROUND
Secondary prevention plays an important role after acute coronary event due to high risk of adverse events in elderly. In present study we aimed to evaluate the lifestyle, management of risk factors and medical treatment for secondary protection in elderly patients with known coronary heart disease (CHD).
METHODS
ELDERTURK is a non-interventional, multi-centered, observational study, which included total of 5694 elderly patients ( > 65 years) from 50 centers in Turkey. In this study elderly patients from the ELDERTURK population with known CHD were evaluated for cardiovascular risk factors, comor- bidities and medication usage.
RESULTS
A total of 2976 (52.3% of study) out of 5694 patients included in the ELDERTURK study were evaluated. All had known CHD with a mean age of 73.4 ± 6.2 years and 60.3% were male. 13.0% of patients were smokers, 42.4% were overweight and 21.1% were obese. Only 23.6% of patients reported to do regular exercise, 73.4% had history of hypertension, 47.4% had dyslipidemia and 33.9% had diabetes mellitus. The rate of patients with systolic blood pressure > 140 mmHg were 31.1% and only 13.9% of patients had a recommended ≤ 70 mg/dL level of low-density lipoprotein cholesterol. Anti- platelet, statin, beta-blocker and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker usage was limited to 27.3%.
CONCLUSIONS
The ELDERTURK study shows that many patients with CHD have a high prevalence of modifiable risk factors and unhealthy lifestyle. Apart from this, many patients are not receiving thera- peutic intervention and as a consequence most were not achieving the recommended goals.
Identifiants
pubmed: 28980279
pii: VM/OJS/J/55115
doi: 10.5603/CJ.a2017.0113
pmc: PMC8086687
doi:
Substances chimiques
Angiotensin-Converting Enzyme Inhibitors
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Platelet Aggregation Inhibitors
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
13-19Références
JAMA. 2004 Apr 21;291(15):1864-70
pubmed: 15100205
Ann Intern Med. 1991 Nov 1;115(9):687-93
pubmed: 1929036
Lancet. 2007 Dec 1;370(9602):1829-39
pubmed: 18061058
Circulation. 2012 Jan 3;125(1):e2-e220
pubmed: 22179539
Blood Press. 2013 Aug;22(4):193-278
pubmed: 23777479
Circulation. 2007 May 15;115(19):2549-69
pubmed: 17502590
Arch Intern Med. 2012 Jun 11;172(11):837-44
pubmed: 22688992
Circulation. 2002 Apr 9;105(14):1735-43
pubmed: 11940556
Anatol J Cardiol. 2016 Aug;16(8):595-600
pubmed: 27004711
J Am Coll Cardiol. 2011 May 17;57(20):2037-114
pubmed: 21524875
Circulation. 2003 Jun 24;107(24):3109-16
pubmed: 12821592
Circulation. 2013 Nov 26;128(22):2422-46
pubmed: 24166575
Atherosclerosis. 2011 Jul;217(1):3-46
pubmed: 21882396
Eur J Cardiovasc Prev Rehabil. 2009 Apr;16(2):121-37
pubmed: 19287307
Stroke. 2004 Oct;35(10):2362-7
pubmed: 15331796
Turk Kardiyol Dern Ars. 2010 Apr;38(3):164-72
pubmed: 20675993
Eur Heart J. 2001 Apr;22(7):554-72
pubmed: 11259143
Eur Heart J. 2011 Sep;32(17):2143-52
pubmed: 21471134
JAMA. 2005 Jul 27;294(4):466-72
pubmed: 16046653
Lancet. 2002 Nov 23;360(9346):1623-30
pubmed: 12457784